FDA-authorized profile

Fibresolve

Imvaria, Inc · CT/CTA · FDA-authorized (De Novo)

Fibresolve is a software-only device that receives and analyzes lung computed tomography (CT) imaging data in order to provide a diagnostic subtype classification in suspected cases of interstitial lung disease (ILD). The device supplements the standardof-care workflow by providing a qualitative, diagnostic classification output of imaging findings based on machine learning pattern recognition, in order to provide adjunctive information as part of a referral pathway to an appropriate Multidisciplinary Discussion (MDD) or as part of an MDD. Specifically, the tool is used to serve as an adjunct in the diagnosis of idiopathic pulmonary fibrosis (IPF) prior to invasive testing. The results of Fibresolve are intended to be used only by clinicians qualified in the care of lung disease, specifically in caring for patients with ILD, in conjunction with the patient's clinical history, symptoms, and other diagnostic tests, as well as the clinician's professional judgment. The input to Fibresolve is a DICOM-compliant lung CT scan. Clinical case eligibility includes the following criteria: Age > 22 years old. Pulmonary symptoms suggestive of possible ILD including IPF.

Clinical role
Analyzes lung CT imaging data and gives a binary output ("Suggestive of IPF" or "Inconclusive"), without visual aid, as adjunctive information in a referral pathway to, or within, a Multidisciplinary Discussion, as an adjunct in IPF diagnosis before invasive testing.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Cannot be used to rule out IPF; clinical decisions should not be based solely on the device's output; series slice thickness must be < 3mm; clinical case eligibility requires age > 22 years and pulmonary symptoms suggestive of possible ILD including IPF.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyCT/CTA · Chest/Lung
  • Workflow roleAnalyzes lung CT imaging data and gives a binary output ("Suggestive of IPF" or "Inconclusive"), without visual aid, as adjunctive information in a referral pathway to, or within, a Multidisciplinary Discussion, as an adjunct in IPF diagnosis before invasive testing.
  • Required inputA single stack of axial, DICOM-compliant lung CT images of 3 mm thickness or less from validated device manufacturers, for patients aged > 22 years with pulmonary symptoms suggestive of possible ILD including IPF.
  • Output and human actionClassification of suspected cases of interstitial lung disease.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Fibresolve is a software-only device that receives and analyzes lung computed tomography (CT) imaging data in order to provide a diagnostic subtype classification in suspected cases of interstitial lung disease (ILD). The device supplements the standardof-care workflow by providing a qualitative, diagnostic classification output of imaging findings based on machine learning pattern recognition, in order to provide adjunctive information as part of a referral pathway to an appropriate Multidisciplinary Discussion (MDD) or as part of an MDD. Specifically, the tool is used to serve as an adjunct in the diagnosis of idiopathic pulmonary fibrosis (IPF) prior to invasive testing. The results of Fibresolve are intended to be used only by clinicians qualified in the care of lung disease, specifically in caring for patients with ILD, in conjunction with the patient's clinical history, symptoms, and other diagnostic tests, as well as the clinician's professional judgment. The input to Fibresolve is a DICOM-compliant lung CT scan. Clinical case eligibility includes the following criteria: Age > 22 years old. Pulmonary symptoms suggestive of possible ILD including IPF.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Analyzes lung CT imaging data and gives a binary output ("Suggestive of IPF" or "Inconclusive"), without visual aid, as adjunctive information in a referral pathway to, or within, a Multidisciplinary Discussion, as an adjunct in IPF diagnosis before invasive testing.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Fibresolve is a software-only device that receives and analyzes lung computed tomography (CT) imaging data in order to provide a diagnostic subtype classification in suspected cases of interstitial lung disease (ILD)." … "provide adjunctive information as part of a referral pathway to an appropriate Multidisciplinary Discussion (MDD) or as part of an MDD. Specifically, the tool is used to serve as an adjunct in the diagnosis of idiopathic pulmonary fibrosis (IPF) prior to invasive testing.". Read from the exact FDA decision document on 2026-11-14.

Required input
A single stack of axial, DICOM-compliant lung CT images of 3 mm thickness or less from validated device manufacturers, for patients aged > 22 years with pulmonary symptoms suggestive of possible ILD including IPF.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The input to the device is a single stack of axial slice, DICOM-compliant, 3 mm thickness or less lung CT images from a list of validated device manufacturers." … "The input to Fibresolve is a DICOM-compliant lung CT scan. Clinical case eligibility includes the following criteria: Age > 22 years old. Pulmonary symptoms suggestive of possible ILD including IPF.". Read from the exact FDA decision document on 2026-11-14.

Output and clinician action
Classification of suspected cases of interstitial lung disease.
  • Exact FDA submission
  • Checked 2026-09-01

Clinical output reported in the exact-submission ACR model card.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Clinicians
  • Exact FDA submission
  • Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Limitations
Cannot be used to rule out IPF; clinical decisions should not be based solely on the device's output; series slice thickness must be < 3mm; clinical case eligibility requires age > 22 years and pulmonary symptoms suggestive of possible ILD including IPF.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "there are warnings that clinical decisions should not be based solely upon the device's output and that the device cannot be used to rule out IPF." … "Series slice thickness must be < 3mm.". Read from the exact FDA decision document on 2026-11-14.

Evidence summary
Study type: Stand-Alone Performance. Cases: 300. Reference standard: Interpretation by Reviewing Clinician
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Study type: Stand-Alone Performance. Cases: 300. Reference standard: Interpretation by Reviewing Clinician
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Fibresolve regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission DEN220040
  • Samplen=300
  • IndependenceIndependence not established

DEN220040

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for DEN220040. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: A single stack of axial, DICOM-compliant lung CT images of 3 mm thickness or less from validated device manufacturers, for patients aged > 22 years with pulmonary symptoms suggestive of possible ILD including IPF.

    Scope: Exact FDA submission. Packet wording: "The input to the device is a single stack of axial slice, DICOM-compliant, 3 mm thickness or less lung CT images from a list of validated device manufacturers." … "The input to Fibresolve is a DICOM-compliant lung CT scan. Clinical case eligibility includes the following criteria: Age > 22 years old. Pulmonary symptoms suggestive of possible ILD including IPF.". Read from the exact FDA decision document on 2026-11-14.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-11-14 · FDA DEN220040: Fibresolve

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · Fibresolve model card (DEN220040)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Classification of suspected cases of interstitial lung disease.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-01 · Fibresolve model card (DEN220040)

  5. Viewer/worklist/report

    Unresolved route: Classification of suspected cases of interstitial lung disease.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-01 · Fibresolve model card (DEN220040)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Fibresolve; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
DEN220040
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
De Novo
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-01-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-authorized
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-08Last searched
22Fields reviewed
10Source classes checked
8Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR and official vendor material provide bounded catalog or product-family context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 8 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda de novo summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact DEN220040 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 2 history items

Source ledger

  1. FDA DEN220040: Fibresolve

    U.S. Food and Drug Administration - Published 2024-01-12 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Fibresolve model card (DEN220040)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for DEN220040

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. DEN220040 FDA decision

    Regulatory record

    De Novo

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K251203

AVIEW Lung Nodule CAD

Coreline Soft Co.,Ltd

Authorized purpose: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2025-12-03
FDA-cleared K250766

LungQ 4

Thirona BV

Authorized purpose: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2025-10-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history